BioRestorative Therapies, Inc. (BRTX), a company focused on stem cell-based therapies, recently received a notice from Nasdaq due to its failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024. The company has 60 days to submit a plan to regain compliance with Nasdaq Listing Rules. Despite this, BioRestorative’s securities will continue to trade on Nasdaq under the symbol “BRTX.” The company is diligently working to complete and file the Form 10-Q as soon as possible.
BioRestorative develops therapeutic products using cell and tissue protocols, including adult stem cells. Their core clinical development programs involve the treatment of disc/spine disease and metabolic disorders, as well as offering BioCosmeceutical products. The Disc/Spine Program focuses on BRTX-100, a product formulated from a patient’s own cultured mesenchymal stem cells for the non-surgical treatment of painful lumbosacral disc disorders. The Metabolic Program, ThermoStem, targets obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. BioRestorative also operates a commercial BioCosmeceutical platform, offering a cell-based secretome for cosmetic effectiveness.
This press release contains forward-looking statements, subject to risks and uncertainties. Investors are advised to consider these factors when evaluating the statements. The company does not have an obligation to update the forward-looking statements. For more information, contact ir@biorestorative.com.